Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02481050
- Locations
- 🇺🇸
Facility #1, Winchester, Virginia, United States
🇺🇸Facility #2, Dallas, Texas, United States
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Fallopian Tube CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell CarcinomaOvarian CarcinomaPathologic Stage III Cutaneous Melanoma AJCC V8
- Interventions
- Drug: CarboplatinDrug: EribulinDrug: FluorouracilDrug: PaclitaxelDrug: CyclophosphamideDrug: CapecitabineBiological: PembrolizumabDrug: OlaparibBiological: NivolumabBiological: IpilimumabDrug: SelinexorDrug: DoxorubicinDrug: TopotecanDrug: PemetrexedDrug: Irinotecan HydrochlorideDrug: OxaliplatinDrug: Leucovorin Calcium
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 221
- Registration Number
- NCT02419495
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
- Conditions
- Interventions
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT02338037
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- Drug: AZD2014Drug: AnthracyclinesDrug: MEDI4736Drug: AZD4547Drug: TaxanesDrug: AZD5363Drug: cyclophosphamideDrug: DNA intercalatorsDrug: AZD8931Drug: SelumetinibDrug: MethotrexateDrug: vinca alkaloidsDrug: VandetanibDrug: Platinum based chemotherapiesDrug: BicalutamideDrug: OlaparibDrug: BevacizumabDrug: Mitomycin CDrug: Eribulin
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 118
- Registration Number
- NCT02263495
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer
- Conditions
- Interventions
- Locations
- 🇸🇬
Johns Hopkins Singapore, Singapore, Singapore
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
- Conditions
- Metastatic Ureter CarcinomaMetastatic Urethral CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Ureter Cancer AJCC v7Stage III Urethral Cancer AJCC v7Stage IV Bladder Urothelial Carcinoma AJCC v7Stage IV Ureter Cancer AJCC v7Stage IV Urethral Cancer AJCC v7Ureter Urothelial CarcinomaUrethral Urothelial Carcinoma
- Interventions
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT02178241
- Locations
- 🇺🇸
UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02171260
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.